Skip to main content

Roche extends deadline for Spark Therapeutics shareholders in $4.8B deal

Roche received offers representing about 29 percent of Sparks’s outstanding shares before the deadline was extended.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.